2-bromo-2-deoxy-D-glucose

2-bromo-D-glucose (2-BG), also known as 2-bromo-2-deoxy-D-glucose, is a halogenated analog of 2-deoxy-D-glucose (2-DG) that was developed and investigated by researchers at the UT MD Anderson Cancer Center. It is designed to inhibit glycolysis, a metabolic pathway that is often upregulated in hypoxic tumors like pancreatic ductal adenocarcinoma (PDAC). As a glucose mimetic, 2-BG is intended to compete with glucose for uptake by glucose transporters and subsequent phosphorylation by hexokinase, thereby depleting cellular ATP and inhibiting tumor cell proliferation. However, preclinical evaluations presented at the AACR 2016 meeting indicated that 2-BG is significantly less potent than other 2-halo derivatives, such as 2-fluorodeoxyglucose (2-FG), showing limited effects on the extracellular acidification rate (ECAR) in pancreatic cancer models.

Other names

2-bromo-D-glucose2-bromo-2-deoxyglucose